Kenji Takaya

USPTO Granted Patents = 10 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 59(Granted Patents)

Location History:

Osaka, JP (2014 - 2018)
Toyonaka, JP (2019 - 2020)

Company Filing History:

8 out of 1,001

Shionogi Company Limited

patents

2 out of 2,112

Northwestern University

patents

Years Active: 2014-2020

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10696707 - Polyene macrolide derivative (2020-06-30),

2. 10246478 - Polyene macrolide derivative (2019-04-02),

3. 9993449 - (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma (2018-06-12),

4. 9815835 - Substituted polycyclic carbamolypyridone derivative (2017-11-14),

5. 9670141 - (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as GABA aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma (2017-06-06),

6. 9499533 - Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity (2016-11-22),

7. 9469638 - Substituted polycyclic carbamoylpyridone derivative (2016-10-18),

8. 8927710 - Substituted polycyclic carbamoylpyridone derivative (2015-01-06),

9. 8889674 - Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism (2014-11-18),

10. 8653125 - Cyclohexane derivative having NPY Y5 receptor antagonism (2014-02-18),

Title: The Innovative Journey of Inventor Kenji Takaya

Introduction

Kenji Takaya is a prominent inventor based in Osaka, Japan, known for his significant contributions to antifungal compounds. With a total of 10 patents to his name, Takaya has made strides in the field of pharmaceutical innovation.

Latest Patents

Among his latest innovations are polyene macrolide derivatives, particularly Amphotericin B derivatives. These compounds are characterized by their urea structure, cyclic structure, hydroxyalkyl, or substituted monoalkylcarbamoyl at the 16th position. The inherent antifungal activity of these compounds positions them as vital assets in medical treatments.

Career Highlights

Throughout his career, Kenji Takaya has made a mark in the pharmaceutical industry. He has worked for notable organizations, such as Shionogi & Company Limited and Northwestern University. His work has significantly impacted the development of effective antifungal agents.

Collaborations

Takaya has collaborated with several talented individuals, including Naoyuki Suzuki and Toshiyuki Akiyama. These partnerships have been instrumental in advancing his research and amplifying the effectiveness of his innovations.

Conclusion

Kenji Takaya's contributions to the field of antifungal compounds reflect his dedication to innovation in healthcare. With a portfolio of patents showcasing his inventive spirit, he continues to be a vital figure in the realm of pharmaceuticals. His work not only highlights the importance of collaboration in scientific advancements but also sets a benchmark for future inventors.

This text is generated by artificial intelligence and may not be accurate.